Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB)-Reference-Cited by-同舟云学术

Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB)

Published:2019-10 Issue: Volume:30 Page:v856-v857
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Slamon D.J.,Neven P.,Chia S.,Fasching P.A.,De Laurentiis M.,Im S.-A.,Petrakova K.,Bianchi G.V.,Esteva F.J.,Martin M.,Nusch A.,Sonke G.S.,De la Cruz-Merino L.,Beck J.T.,Pivot X.,Sondhi M.,Wang Y.,Chakravartty A.,Rodriguez-Lorenc K.,Jerusalem G.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/30/Supplement_5/mdz394.007/30083342/mdz394.007.pdf

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent progress of CDK4/6 inhibitors’ current practice in breast cancer;Cancer Gene Therapy;2024-02-26

2. Progress and prospects in research and clinical practice of hormone receptor-positive, HER-2-negative breast cancer with BRCA1/2 mutations;Discover Oncology;2023-06-23

3. Safety of CDK4/6 Inhibitors Combined with Radiotherapy in Patients with Metastatic Breast Cancer: A Review of the Literature;Current Oncology;2023-06-06

4. Einführung von CDK4/6-Hemmern und deren Auswirkung auf die Behandlungslandschaft bei Patientinnen mit Brustkrebs im fortgeschrittenen Stadium – Real-World-Daten aus dem PRAEGNANT-Register;Senologie - Zeitschrift für Mammadiagnostik und -therapie;2023-02-28

5. Patient preferences do matter: a discrete choice experiment conducted with breast cancer patients in six European countries, with latent class analysis;International Journal of Technology Assessment in Health Care;2023